Live Chat ×
Skip to main content

Phase Appropriate Selection of Analytical Methodology

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Karoline Bechtold-Peters, Novartis

  • Dr. Oliver K. Valet

    Dr. Oliver K. Valet is one of the co-founders of rap.ID Particle Systems GmbH a company that develops manufactures and sells unique particle identification systems. Within the last 15 years their patented technology fuses particle isolation, imaging analysis and spectroscopic technology together to powerful investigation tools. Streamlining particle contamination identification and particle characterization.

    Within rap.ID Dr. Valet is responsible for the product development and worldwide marketing and sales.
    From the FDA inspected industrial forensics laboratory work performed at both rap.ID sites in Berlin, Germany and Princeton, New Jersey Dr. Valet has more than a decade experience in the field of industrial and environmental chemical analysis on particles. As an active member of the Respiratory Drug Delivery, RDD, the Royal Chemical Society, Parenteral Drug Association, PDA and American Association of Pharmaceutical Science, AAPS and the Apothekerverband, APV he has published his work continuously and presented on various conferences.

  • Roman Mathaes, Ph.D. (Lonza)

    Roman Mathaes is a group leader within the Lonza Drug Product Service organization.
    He is leading the Lonza particle lab and the container closure integrity testing. In this role, Roman is responsible for particle analytics in drug products and container closure integrity testing of vials and pre-filled syringes. Prior to this assignment, Roman was working within Roche/Genentech network supporting process development of the commercial manufacturing.

    Roman is co-leading the analytical method subteam at the AAPS PABC and is an active member of the European CCI industry focus group and part of the BPOG CCI workstream.
    Roman is a pharmacist by training and conducted his studies at the University of Marburg and King’s College London. He holds a Ph.D. in pharmaceutical technology from the University of Munich for work on subvisible particle characterization.

March 29, 2017
Wed 12:30 PM EDT

Duration 1H 30M

This live web event has ended.